|  |  |  |  |
| --- | --- | --- | --- |
| **Please note:** | | Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly or arrive after the deadline.  [Developing NICE guidance: how to get involved](http://www.nice.org.uk/article/pmg22/chapter/3-how-you-can-get-involved#scope-consultation) has a list of possible areas for comment on the draft scope. | |
| Stakeholder organisation (if you are responding as an individual rather than a registered stakeholder please state name here): | | **[insert here]** | |
| Name of commentator (if you are responding as an individual rather than a registered stakeholder please leave blank): | | **[insert here]** | |
| The guideline committee will make final decisions about the presentations, infections, diagnostic tests and time frames under consideration. As part of the consultation, we would welcome stakeholder’s thoughts  on the following:  1)      Is the time period of ‘< than 6 months since tick bite or first symptoms or signs’ an acceptable interpretation for ‘early Lyme borreliosis’?  2)      Is the time period of ‘> 6 months since tick bite or first symptoms or signs’ or an acceptable interpretation for ‘late Lyme borreliosis’?  3)      The use of the British Infection Association1 position paper classification to determine the range of clinical presentations that will be considered.  4)      The inclusion of the following strains of Lyme Borreliosis for consideration as part of our review of the evidence:   * B. burgdorferi (and the subtype B. burgdorferi sensu stricto), * B. garinii, * B. afzelii   5)      The appropriate diagnostic tests for consideration  1 The epidemiology, prevention, investigation and treatment of Lyme borreliosis in United Kingdom patients: A position statement by the  British Infection Association Journal of Infection (2011), **62**, 329-338 Available from <http://www.aldf.com/pdf/BIA%202011statement%20on%20Lyme%20disease.pdf> | | | |
| **Comment**  **No.** | Page  number  or **‘general’** for comments on the whole document | **Line**  **number**  or **‘general’** for comments on the whole document | Comments Insert each comment in a new row.  Do not paste other tables into this table, as your comments could get lost – type directly into this table. |
| Example | 3 | 55 | The draft scope currently excludes people who have already been diagnosed. We feel this group should be included because…. |
|  | | | |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 |  |  |  |
| 5 |  |  |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 8 |  |  |  |
| 9 |  |  |  |
| 10 |  |  |  |
| 11 |  |  |  |
| 12 |  |  |  |
| 13 |  |  |  |
| 14 |  |  |  |
| 15 |  |  |  |

Add extra rows if needed

|  |
| --- |
| **Checklist for submitting comments**   * Use this form and submit it as a Word document (not a PDF). * Include page and line number (not section number) of the text each comment is about. * Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation. * Do not paste other tables into this table – type directly into the table. * Underline and highlight any confidential information or other material that you do not wish to be made public. * Do not include medical information about yourself or another person from which you or the person could be identified. * Spell out any abbreviations you use * For copyright reasons, do not include attachments such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments.   **Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.  Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees. |